Clinical outcomes and medical resource utilization of toripalimab combination therapy versus bevacizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer

CONCLUSION: Toripalimab combination therapy could significantly prolonged PFS for patients with advanced non-squamous NSCLC compared with BCP, but at the expense of more MRU, costs and AEs.PMID:38193524 | DOI:10.1080/03007995.2024.2303122

Source: Current Medical Research and Opinion - January 9, 2024 Category: Research Authors: Huijie Qi Wenxin Zhang Bicui Chen Qiong Zhan Tianxiao Wang Huanying Shi Yanchen Liu Yan Wang Mingkang Zhong Xiaojin Shi Fangfang Shen Qunyi Li Source Type: research